Stay updated on Glycine Supplement for Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.

Latest updates to the Glycine Supplement for Severe COVID-19 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a PubMed-generated publications note and the revision tag 'Revision: v3.3.2'; removed the prior funding-status notice and the older PubMed note ('These publications come from PubMed...') and the 'Revision: v3.2.0' reference. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedThe study record now indicates termination after an interim analysis showing no major differences between glycine and control groups. Enrollment and primary/secondary outcome data have been updated to reflect the current status.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government funding lapse notice and operating-status guidance, and confirmed the NIH Clinical Center is open with where to check status. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page updates from Revision: v3.0.1 to v3.0.2 and removes the Back to Top element; these changes do not affect core content or critical information such as pricing, stock, or time slots.SummaryDifference0.1%

- Check99 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

Stay in the know with updates to Glycine Supplement for Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Glycine Supplement for Severe COVID-19 Clinical Trial page.